IP Forecast: Novartis To Fight Antitrust Row Over Drug Patent

By Andrew Karpan · October 5, 2023, 9:38 PM EDT

Novartis is set to oppose an appeal at the Second Circuit from a rival seeking to restore an antitrust suit accusing it of hiding things from the patent office to illegally...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Case Information

Case Title

Regeneron Pharmaceuticals, Inc v. Novartis Pharma AG

Case Number

Court

Appellate - 2nd Circuit

Nature of Suit

3410 STATUTES-Antitrust

Date Filed

March 01, 2022

Recent Articles By Andrew

November 19, 2024
Judge Rejects Infosys' Bid To Seal NDAs In Trade Secrets Row
November 18, 2024
Melinta Obtains Ban On Generic Antibiotic Injections In IP Row
November 12, 2024
GOP Reps. Propose Another Bill On TRIPS Waivers
October 23, 2024
Court Denies Fees In 'Objectively Specious' Trade Secrets Suit
October 02, 2024
Avadel Tells Fed. Circ. It Should Be Free To Test Sleep Drug
September 26, 2024
2nd Circ. Denies Jury Trial In Abbott Labs Gray Market Case
September 09, 2024
Purdue Sees Another OxyContin Patent Axed
September 05, 2024
Nvidia, Microsoft Face Patent, Cartel Allegations In Texas Suit
August 09, 2024
Valeant's Legal Gripe A Total 'Nothingburger,' Justices Told
July 11, 2024
GSK Asks Judge To Rule In Teva IP Case, Citing Opioid Deals